0QV2 Stock Overview
A medical device company, provides infection prevention solutions in orthopedics, urology, intravascular/critical care, dental, and wound care therapeutic areas in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bactiguard Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr74.00 |
| 52 Week High | kr83.70 |
| 52 Week Low | kr60.40 |
| Beta | -0.22 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 8.88% |
| 33 Year Change | -61.05% |
| 5 Year Change | n/a |
| Change since IPO | 224.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QV2 | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.9% | 1.1% |
| 1Y | 8.9% | -11.0% | 8.1% |
Return vs Industry: 0QV2 exceeded the UK Medical Equipment industry which returned -10.7% over the past year.
Return vs Market: 0QV2 exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0QV2 volatility | |
|---|---|
| 0QV2 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0QV2 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0QV2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 217 | Christine Lind | www.bactiguard.com |
Bactiguard Holding AB (publ), a medical device company, provides infection prevention solutions in orthopedics, urology, intravascular/critical care, dental, and wound care therapeutic areas in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally. The company's infection prevention solutions reduce the risk of infections and the use of antibiotics. Its product portfolio consists of Bactiguard infection protection (BIP) Foley Catheter, an indwelling urinary catheter that reduces microbial adhesion; BIP Central Venous Catheter, which reduces the risk of catheter related bloodstream infection and antibiotics; BIP Endotracheal Tube, that reduces the ventilator associated pneumonia, antibiotics, and healthcare costs; BIP Endotracheal Tube Evac, a tube that combines the subglottic secretion drainage with coating to reduce microbial adhesion; and BIP Foley TempSensor, an indwelling urinary catheter that offers surveillance and infection prevention.
Bactiguard Holding AB (publ) Fundamentals Summary
| 0QV2 fundamental statistics | |
|---|---|
| Market cap | kr2.38b |
| Earnings (TTM) | -kr138.38m |
| Revenue (TTM) | kr203.99m |
11.7x
P/S Ratio-17.2x
P/E RatioIs 0QV2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QV2 income statement (TTM) | |
|---|---|
| Revenue | kr203.99m |
| Cost of Revenue | kr49.21m |
| Gross Profit | kr154.78m |
| Other Expenses | kr293.16m |
| Earnings | -kr138.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | -3.95 |
| Gross Margin | 75.88% |
| Net Profit Margin | -67.84% |
| Debt/Equity Ratio | 50.6% |
How did 0QV2 perform over the long term?
See historical performance and comparison